Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 18Tumor-Agnostic 11Thoracic 5Sarcoma 5Gynecologic 4Breast 4Genitourinary 3CNS 3Lymphoid 2Dermatologic 2Other hematologic neoplasm 1Head & Neck 1

Conditions

Melanoma 16Neoplasm Metastasis 4Uveal Melanoma 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma, Cutaneous Malignant 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Hodgkin Disease 1Histiocytoma 1Head and Neck Neoplasms 1Fibrosarcoma 1Esophageal Neoplasms 1Dermatofibrosarcoma 1

Interventions

pembrolizumab 40Nivolumab 18trametinib 13Cyclophosphamide 13dabrafenib 11Vemurafenib 10Interleukin-2 10Ipilimumab 9fludarabine 7Docetaxel 7fludarabine phosphate 6cemiplimab 6Paclitaxel 6Cisplatin 6Carboplatin 6atezolizumab 5Radiotherapy 5Drug Therapy 5Dacarbazine 5Blood Specimen Collection 5Biopsy 5poly ICLC 4binimetinib 4Therapeutics 4Psychiatric Rehabilitation 4sotigalimab 3montanide ISA 51 3encorafenib 3cobimetinib 3budigalimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Albumin-Bound Paclitaxel × Dermatologic × Clear all
NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Seagen Inc.

Phase 1 Terminated
159 enrolled
DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT01962103 2019-12-27

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Celgene

Phase 1/2 Completed
107 enrolled 42 charts
CNSDermatologicSarcoma

Fibrosarcoma, Melanoma, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Dermatofibrosarcoma, Histiocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡